TXB4-LS1

N/A

Report date: 2025/01/26 16:09:00

Base Information

Drug NameTXB4-LS1
Drug Alias Nameanti-transferrin receptor/anti-IDUA VNAR bispecific antibodies (Ossianix)TXB4-LS1
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionTransferrin receptor protein 1 antagonistsAlpha-L-iduronidase inhibitors
TargetsAlpha-L-iduronidaseTransferrin receptor protein 1
Therapy Area/IndicationsMucopolysaccharidosis I
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesOssianix Inc
China Registration ClassN/A

Develop Information

Active CompaniesOssianix Inc
Inactive CompaniesN/A
Active IndicationsMucopolysaccharidosis I
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A